$29.28
1.78% day before yesterday
Nasdaq, Jan 02, 10:01 pm CET
ISIN
US88322Q1085
Symbol
TGTX

TG Therapeutics, Inc. Stock price

$29.28
-1.35 4.41% 1M
-7.01 19.32% 6M
-0.53 1.78% YTD
-1.78 5.73% 1Y
+17.45 147.51% 3Y
-21.72 42.59% 5Y
+17.87 156.62% 10Y
-3,486.35 99.17% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.53 1.78%
ISIN
US88322Q1085
Symbol
TGTX
Industry

New AI Insights on TG Therapeutics, Inc. Insights AI Insights on TG Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$4.6b
Enterprise Value
$4.8b
Net debt
$113.4m
Cash
$131.6m
Shares outstanding
155.0m
Valuation (TTM | estimate)
P/E
10.5 | 10.1
P/S
8.7 | 7.5
EV/Sales
9.0 | 7.7
EV/FCF
negative
P/B
7.7
Financial Health
Equity Ratio
38.5%
Return on Equity
10.5%
ROCE
11.8%
ROIC
69.4%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$531.9m | $618.1m
EBITDA
$102.6m | $141.2m
EBIT
$102.6m | $135.2m
Net Income
$447.4m | $450.9m
Free Cash Flow
$-69.8m
Growth (TTM | estimate)
Revenue
100.9% | 87.9%
EBITDA
25,129.3% | 236.3%
EBIT
20,410.7% | 222.5%
Net Income
3,215.5% | 1,828.4%
Free Cash Flow
-148.4%
Margin (TTM | estimate)
Gross
85.3%
EBITDA
19.3% | 22.9%
EBIT
19.3%
Net
84.1% | 72.9%
Free Cash Flow
-13.1%
More
EPS
$2.8
FCF per Share
$-0.5
Short interest
20.7%
Employees
338
Rev per Employee
$970.0k
Show more

Is TG Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

TG Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a TG Therapeutics, Inc. forecast:

12x Buy
80%
2x Hold
13%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a TG Therapeutics, Inc. forecast:

Buy
80%
Hold
13%
Sell
7%

Financial data from TG Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
532 532
101% 101%
100%
- Direct Costs 78 78
153% 153%
15%
454 454
94% 94%
85%
- Selling and Administrative Expenses 208 208
42% 42%
39%
- Research and Development Expense 143 143
63% 63%
27%
103 103
25,129% 25,129%
19%
- Depreciation and Amortization 0.05 0.05
50% 50%
0%
EBIT (Operating Income) EBIT 103 103
20,411% 20,411%
19%
Net Profit 447 447
3,216% 3,216%
84%

In millions USD.

Don't miss a Thing! We will send you all news about TG Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TG Therapeutics, Inc. Stock News

Positive
Seeking Alpha
4 days ago
TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025.
Neutral
Seeking Alpha
about 2 months ago
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of...
More TG Therapeutics, Inc. News

Company Profile

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Head office United States
CEO Michael Weiss
Employees 338
Founded 1993
Website www.tgtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today